Zobrazeno 1 - 10
of 61
pro vyhledávání: ''
Autor:
Takashi Seto, Noboru Yamamoto, Takeharu Yamanaka, Yuichiro Ohe, Makoto Nishio, Tatsuya Yoshida, Toyoaki Hida, Akira Ono, Takayasu Kurata, Kentaro Sakamaki, Hiroaki Okamoto, Miyako Satouchi, Seiji Niho, Koichi Goto, Tetsuo Akimoto
Publikováno v:
Lung Cancer. 141:64-71
Objectives SPECTRA is a multicenter, randomized phase II study of chemotherapy with cisplatin (CDDP) plus S-1 versus CDDP plus pemetrexed (PEM) in combination with thoracic radiotherapy (TRT) for locally advanced non-squamous non-small cell lung canc
Autor:
Zhichao Liu, Wenhua Liang, Jun Liu, Zhenkui Pan, Xiuyu Cai, Caichen Li, Jianxing He, Yi Zhao, Bo Cheng, Xiaohong Xie, Jie Lin, Hengrui Liang
Publikováno v:
Lung Cancer. 134:218-224
To investigate the incidence and distribution of lymph node metastasis in patients with different gene mutations among pathological T1 non-small-cell lung cancers (NSCLC).NSCLC cases resected in our institution between 2016 and 2018 were included. Dr
Autor:
Yanwei Zhang, Ruiying Zhao, Jianlin Xu, Yiming Zhao, Rong Qiao, Baohui Han, Shuyuan Wang, Bo Zhang, Rui Wang, Jie Qian, Lele Zhang
Publikováno v:
Lung Cancer. 125:245-252
Lymphovascular invasion (LVI) and Visceral Pleural Invasion (VPI) have been reported to be risk factors for stage I Non-Small Cell Lung Cancer (NSCLC). However, only VPI was incorporated into the current 8th Tumor-Node-Metastasis (TNM) classification
Autor:
Melania Pintilie, Shingo Sakashita, Ming-Sound Tsao, Ronald Feld, Suzanne Kamel-Reid, Frances A. Shepherd, Pascale Tomasini, C. Mascaux, Catherine Labbé, Kevin Jao, David M. Hwang, Penelope A. Bradbury, Geoffrey Liu, Natasha B. Leighl, Gregorz J. Korpanty
Publikováno v:
Lung Cancer. 123:22-29
Introduction Somatic mutations are becoming increasingly important biomarkers for treatment selection and outcome in patients with non-small-cell lung cancer (NSCLC). The role of multiple somatic mutations in early-stage NSCLC is unclear. Methods Tis
Autor:
William Pao, Matthias Freiwald, Vincent A. Miller, Scott N. Gettinger, Leora Horn, Vikram K. Chand, Egbert F. Smit, Bushi Wang, Harry J.M. Groen, D. Ross Camidge, Yelena Y. Janjigian, Jean Fan
Publikováno v:
Horn, L, Gettinger, S, Camidge, D R, Smit, E F, Janjigian, Y Y, Miller, V A, Pao, W, Freiwald, M, Fan, J, Wang, B, Chand, V K & Groen, H J M 2017, ' Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib ', Lung Cancer, vol. 113, pp. 51-58 . https://doi.org/10.1016/j.lungcan.2017.08.014
Lung Cancer, 113, 51-58. ELSEVIER IRELAND LTD
Lung Cancer, 113, 51-58. Elsevier Ireland Ltd
Lung Cancer, 113, 51-58. ELSEVIER IRELAND LTD
Lung Cancer, 113, 51-58. Elsevier Ireland Ltd
Objectives In a phase Ib trial, afatinib plus cetuximab demonstrated promising clinical activity (objective response rate [ORR]: 29%; median progression-free survival [PFS]: 4.7 months) in patients with epidermal growth factor receptor (EGFR) mutatio
Autor:
Chad G. Rusthoven, Matthew Koshy, David J. Sher, Michael T. Spiotto, Renuka Malik, Usama Mahmood
Publikováno v:
Lung Cancer. 108:222-227
To determine the effect of radiotherapy (RT) technique on treatment compliance and overall survival (OS) in patients with stage III non-small lung cancer (NSCLC) treated with definitive chemoradiotherapy (CRT).This study included patients with stage
Autor:
Silvia Ess, Thomas Cerny, P. Neumair, Florent Baty, Felicitas Hitz, M. Früh, Rene Warschkow, Martin Brutsche, Markus Joerger, L. Joos, Stephan Krähenbühl, A. Dutly
Publikováno v:
Lung Cancer. 100:38-44
Objectives Controversy exists about the integration of erlotinib in patients with EGFR wildtype, advanced NSCLC. Materials and methods We included patients with advanced NSCLC receiving at least two lines of palliative systemic treatment between Janu
Autor:
David Ferry, Sotaro Enatsu, Toshiko Koue, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Kiyotaka Yoh, Takashi Nakamura, Yuichiro Ohe, Pablo Lee, Makoto Nishio, Kazuo Kasahara, Yukio Hosomi, Toshiaki Takahashi, Tomohide Tamura, Kazuhiko Yamada
Publikováno v:
Lung Cancer. 99:186-193
Objectives Ramucirumab plus docetaxel prolongs survival in patients with non-small cell lung cancer (NSCLC) with disease progression after platinum-based therapy. This phase II, double-blind, randomized, placebo-controlled study assessed efficacy and
Autor:
Takeshi Uenami, Makoto Nishio, Atsushi Horiike, Yuko Kawano, Kengo Takeuchi, Yuichi Ishikawa, Noriko Yanagitani, Fumiyoshi Ohyanagi, Azusa Tanimoto, Kyohei Kaburaki, Yuichi Tambo, Takeshi Horai, Keita Kudo, Noriko Motoi
Publikováno v:
Lung Cancer. 93:43-46
Background RET fusions were recently identified in non-small cell lung cancer (NSCLC) and are considered as a potential therapeutic target of NSCLC. Sorafenib, a multi-kinase inhibitor, has potent anti- RET activity. We conducted a study to evaluate
Autor:
Dae Ho Lee, Sang We Kim, Minkyu Jung, Seok Yun Kang, Byoung Chul Cho, Hyo Sup Shim, Dong Wan Kim, Jin-Hyuk Choi, Jong Rak Choi, Dae Seog Heo, Joo Hang Kim, Heung Tae Kim, Sun Min Lim
Publikováno v:
Lung Cancer. 93:1-8
Objectives Sorafenib and erlotinib are potent, orally administered receptor tyrosine kinase inhibitors with antiproliferative and antiangiogenic activities. Given their synergistic activity in combination, we conducted a phase II study to determine t